Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29321860 | 0.84 | CYP1A2 (0.48) | BRD4CYP1A2CYP2A6ALDH1A1CSF1R | |
| SCHEMBL29321863 | 0.77 | ALDH1A1 (0.40) | BRD4CYP1A2CYP2A6ALDH1A1CSF1R | |
| SCHEMBL2005193 | 0.76 | BRD4 (0.42) | BRD4CYP1A2ALDH1A1KDM4ECA1 | |
| SCHEMBL2005190 | 0.74 | BRD4 (0.41) | BRD4CA1CA2CA7CA9 | |
| SCHEMBL476806 | 0.74 | CYP1A2 (0.44) | BRD4CYP1A2CYP2A6TSHRTP53 | |
| SCHEMBL20871562 | 0.74 | BRD4 (0.41) | BRD4 | |
| SCHEMBL8404485 | 0.74 | CCR1 (0.35) | BRD4CYP1A2CYP2A6CSF1RTSHR | |
| SCHEMBL2736863 | 0.74 | CYP3A4 (0.44) | BRD4CYP1A2ALDH1A1KDM4ETSHR | |
| SCHEMBL24399382 | 0.74 | BRD4 (0.42) | BRD4ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL21026104 | 0.74 | BRD4 (0.42) | BRD4ALDH1A1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20220062296-A1 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2021195183-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE | EXO THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2019195496-A1 | IMPROVED WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND ACETYL CoA CARBOXYLASE (ACCase) INHIBITORS | DOW AGROSCIENCES LLC (US) | 2019-10-10 | — | — | WO | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| EP-2231663-B1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | AMGEN INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3170824-A1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | Amgen, Inc (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9469654-B2 | Bicyclic oxa-lactam kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2164847-B1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| WO-2009004584-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | BRD4 3499/4885CYP1A2 269/4885CYP2A6 202/4885 |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | BRD4 576/4885CYP1A2 1175/4885CYP2A6 1139/4885 |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | CHRM1, CHRM2, CHRM4 | BRD4 869/4885CYP1A2 336/4885CYP2A6 399/4885 |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | DRD3, HTR3C, HTR3A | BRD4 1149/4885CYP1A2 1924/4885CYP2A6 1059/4885 |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | STAT3, JAK2, STAT6 | BRD4 367/4885CYP1A2 4602/4885CYP2A6 3967/4885 |
| US-20220062296-A1 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA2 | BRD4 3419/4885CYP1A2 796/4885CYP2A6 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.